Division of Medical Oncology, Yale University School of Medicine, 333 Cedar Street, FMP 127, New Haven, CT 06520, USA.
Clin Chest Med. 2011 Dec;32(4):839-51. doi: 10.1016/j.ccm.2011.08.017.
The last decade has heralded a paradigm shift in the evaluation and treatment of advanced non-small cell lung cancer (NSCLC). No longer are patients with NSCLC considered a homogeneous population treated in the same way; rather, clinical characteristics, histology, and an expanding array of molecular markers are increasingly being used to individualize therapy. Both histology and tumor epidermal growth factor receptor mutational status currently have firmly established roles in determining initial and salvage therapy for advanced NSCLC. Several other biomarkers are the focus of ongoing prospective randomized clinical trials customizing both traditional chemotherapy and newer molecularly targeted agents.
过去十年见证了晚期非小细胞肺癌（NSCLC）评估和治疗范式的转变。不再认为 NSCLC 患者是同质人群，采用相同的治疗方法；相反，临床特征、组织学和不断扩展的分子标志物越来越多地用于个体化治疗。组织学和肿瘤表皮生长因子受体突变状态目前在确定晚期 NSCLC 的初始和挽救治疗方面都具有明确的作用。其他一些生物标志物是正在进行的前瞻性随机临床试验的重点，这些试验旨在定制传统化疗和新型分子靶向药物。
